AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...

Cardiac involvement in Fabry disease. About numbers and notions. Paper presented at the World Congress on Heart Disease, Barcelona, Spain, September 2–6, 2006. Eng CM, Banikazemi M, Gordon RE ...

The primary reasons for exclusion were age over 85 years at the time of data analysis (29%), followed by a diagnosis of another cardiomyopathy (16%), and symptomatic valvular heart disease causing ...

Background Fabry disease is a treatable X-linked condition leading to progressive cardiomyopathy ... There were 11 deaths during follow-up: two patients died following sustained ventricular arrhythmia ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

including kidney and heart cells, eventually resulting in a multi-system disorder. AMT-191 may offer a novel one-time intravenously administered approach to treating Fabry disease. About the Phase ...

OBJECTIVES To determine the natural history of Anderson-Fabry disease (AFD) as a baseline for efficacy assessment of potentially therapeutic drugs. DESIGN The first large cross sectional study of a ...

Background: Agalsidase beta is used to treat Fabry disease (FD); however, data on cardiac and cerebrovascular outcomes with agalsidase beta treatment come from studies with limited numbers of patients ...

They recruited 36 pregnant women and ... Mothers of Twins Face a Higher Risk of Heart Disease in the Year After Birth Feb. 3, 2025 — The risk of being admitted to the hospital with heart disease ...